moxetumomab pasudotox-tdfk - Pharmacy Practice News

×

ADVERTISEMENT

Register Log in

Elimination Diets Call for Caution and Adaptation

AUGUST 26, 2025

New Strategy Proposed for HR+, HER2– Advanced Breast Cancer

AUGUST 26, 2025

Keeping an Eye on 8 New Payment Trends

AUGUST 25, 2025

moxetumomab pasudotox-tdfk

FDA Approves Lumoxiti for Hairy Cell Leukemia

Lumoxiti is a CD22-directed cytotoxin approved to treat adults with relapsed or refractory hairy cell leukemia.

SEPTEMBER 13, 2018

Load more

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

OR

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select